Toggle Nav
Close
  • Menu
  • Setting

Anti-CD79b Antibody (Polatuzumab vedotin-piiq)

Catalog No.
F1126
Anti-CD79b Antibody (Polatuzumab vedotin-piiq)
Grouped product items
SizePriceStock Qty
100ug
$229.00
Ship with 3-5 days
1mg
$1,143.00
Ship with 3-5 days
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Polatuzumab vedotin-piiq (polatuzumab vedotin, DCDS4501A, RG7596) is an antibody-drug conjugate (ADC) consisting of a monoclonal antibody against CD79b (a component of the B-cell receptor) and the anti-mitotic antibody cytotoxic agent monomethyl auristatin (MMAE). It is used to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Quality Control

Quality Control & DataSheet

View current batch:
 

M.Wt

150.53 kDa

Shipping

Dry ice

Cas No.

1313206-42-6

Storage

-80°C

Expiration Date

2 years

Form

Liquid

Concentration

See label

Reconstitution

For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.

Host

CHO

Alternative Names

Polivy, RG7596, DCDS4501A

Buffer System

100 mM Pro 20 mM Arg pH 5.0. No preservative!

Target Accession

P40259

Reactivity

Human

Conjugation

MMAE

Clonality

Monoclonal

Purification

Protein A

Isotype

IgG1

Application

ELISA, FACS, Kinetics, Functional assay, Animal Model

Biological Activity

The drug-to-antibody ratio (DAR) of the Anti-CD79b Reference Antibody (Polatuzumab vedotin-piiq) is 3.8.

Target

CD79b

Note

Please avoid freeze-thaw cycles.